Emerging Company Profile
Replicate: optimizing the promise of self-replicating RNA
Emerging Company Profile: ATP unveils Replicate Bioscience with $40M and goal of harness dosing, safety advantages of the RNA tech
ATP unveils Replicate Bioscience with $40 million and a goal of harness the dosing and safety advantages of self-replicating RNA.
Replicate is launching with a stable of optimized virally derived vectors to harness the dosing and safety advantages of self-replicating RNA.
The start-up brings together several leaders in self-replicating RNA, also known as self-amplifying RNA, with a $40 million series A round from founding investor Apple Tree Partners. ATP’s